Thursday, 23 October 2014

Mortality risk among sulfonylureas: a systematic review and network meta-analysis

Gliclazide and glimepiride were associated with a lower risk of all-cause and cardiovascular-related mortality compared with glibenclamide. Clinicians should consider possible differences in risk of mortality when selecting a sulfonylurea (The Lancet Diabetes & Endocrinology)

No comments:

Post a Comment